Because No One is Immune to the Law
February 07, 2024 - FDA

FTC Alleges Improper Orange Book Listing of Drug Delivery Device Patents

Prescription Drug

In the latest attempt to promote generic drug competition and reduce drug prices, and consistent with broader efforts to enforce the antitrust laws more aggressively, the Federal Trade Commission (FTC) announced on November 7, 2023, challenges to more than 100 patent listings by brand drug manufacturers in the Food and Drug Administration’s (FDA) Orange Book. The challenges implicate 62 unique patents and 18 FDA-approved products.

Read the full client alert.